ABL Bio (298380.KQ) Q1 2026: Loss Narrows 48%, ₩186.7B in Cash
ABL Bio (298380.KQ) Q1 2026: Loss Narrows 48%, ₩186.7B in Cash
PremiumEO Technics (039030.KQ) Q1 2026: Operating Profit Doubles as HBM Laser Demand Surges
EO Technics (039030.KQ) Q1 2026: Operating Profit Doubles as HBM Laser Demand Surges
PremiumSamchundang Pharmaceutical (000250.KS) FY2025: Ailia Biosimilar Debut Drives 220% Operating Profit Surge, Swings to Net Profit
Samchundang Pharmaceutical (000250.KS) FY2025: Ailia Biosimilar Debut Drives 220% Operating Profit Surge, Swings to Net Profit
PremiumOCI Holdings (010060.KS) Q2 2026: Texas Solar Drives 58% Revenue Jump and Third Straight Quarterly Profit
OCI Holdings (010060.KS) Q2 2026 revenue ₩1.23 trillion (+58% YoY), operating profit ₩108B, and net profit ₩60.6B—third consecutive quarter of profitability driven by La Salle Texas solar monetization
PremiumKolon TissueGene (950160.KQ) Q1 2026: ₩99.9B Net Loss Is 95% Non-Cash Derivatives as TG-C Phase 3 Misses Primary Endpoints
Kolon TissueGene (950160.KQ) Q1 2026: ₩99.9B Net Loss Is 95% Non-Cash Derivatives as TG-C Phase 3 Misses Primary Endpoints
PremiumJusung Engineering (036930.KQ) Q1 2026: Revenue Halves to ₩54.9B as R&D at 46% of Sales Drives ₩7B Operating Loss
Jusung Engineering Q1 2026: consolidated revenue fell 54.6% YoY to ₩54.9B; R&D at 46% of sales drove a ₩7.03B operating loss. Analysis of the semiconductor equipment cycle trough and market implications.
PremiumRainbow Robotics (277810.KQ) Q1 2026: Revenue Surges 116.6% as Samsung Subsidy Lifts Scale, But R&D Intensity Widens Operating Loss
Rainbow Robotics (277810.KQ) posted Q1 FY2026 consolidated revenue of KRW 9.06 billion (+116.6% YoY), the first major scale expansion since Samsung Electronics became the 35% controlling shareholder at end-2024. Despite the top-line surge, the operating loss widened to KRW 1.57 billion as R&D spending reached 30.7% of revenue.
PremiumAlteogen (196170.KQ) Q1 2026: 120% SG&A Surge Erodes Operating Profit 36% Despite ₩867.5B Biogen Deal
Alteogen reported Q1 2026 revenue of ₩71.6B (-14.5% YoY) and operating profit of ₩39.3B (-35.6% YoY) as SG&A expenses surged 120% to ₩22.2B. A ₩35.9B RCPS derivative gain held net income at ₩71.3B. The quarter included a ₩867.5B Biogen licensing agreement, pushing total out-licensing backlog past ₩9.3 trillion.
PremiumEcoPro (086520.KQ) Q1 2026: ₩247.3B Swing, Gross Margin Doubles
EcoPro (086520.KQ) Q1 2026: ₩247.3B Swing, Gross Margin Doubles
PremiumEcoPro BM (247540.KQ) Q1 2026: Profit Surges 9x, Margin Now Real
EcoPro BM (247540.KQ) Q1 2026: Profit Surges 9x, Margin Now Real
PremiumHow to Buy Samsung Stock as a US Investor: SSNLF, London GDR, KRX Direct, and ETFs Compared
Samsung (005930.KS) has no US ADR. Compare SSNLF OTC, SMSN.L London GDR, KRX direct via IBKR (May 2026), and ETFs — with tax and liquidity data for US investors.
PremiumAsiana Airlines (020560.KS) Q1 2026: Revenue Slumps 19%, ₩266B FX Translation Loss Drives ₩252B Net Deficit
Asiana Airlines (020560.KS) Q1 2026: Revenue Slumps 19%, ₩266B FX Translation Loss Drives ₩252B Net Deficit